Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma

Hong Chang, Yi Ning, Xiaoying Qi, Joanna Yeung, Wei Xu

Research output: Contribution to journalArticle

Abstract

The combination of fluorescence in situ hybridization with cytoplasmic light chain detection identified chromosome 1p21 deletion in 18 (20%) of 87 patients with multiple myeloma. 1p21 deletion was associated with higher serum calcium level, 13q deletion, and t(4;14). Patients with 1p21 deletions had a significantly shorter progression-free survival (PFS) (median 10.5 vs. 22.3 months, P = 0.0002) and shorter overall survival (OS) (median 33.9 months vs. not reached, P = 0.002) than those without 1p21 deletions. On multivariate analysis, which included deletions of 13q, TP53, t(4;14) and CKS1B amplification, 1p21 deletion remained as an independent risk factor for PFS (P = 0.01) and OS (P = 0.04).

Original languageEnglish (US)
Pages (from-to)51-54
Number of pages4
JournalBritish Journal of Haematology
Volume139
Issue number1
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Chromosome Deletion
Multiple Myeloma
Disease-Free Survival
Survival
Fluorescence In Situ Hybridization
Multivariate Analysis
Calcium
Light
Serum
13q deletion syndrome

Keywords

  • 1p21
  • CDC14A
  • Fluorescence in situ hybridization
  • Multiple myeloma
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. / Chang, Hong; Ning, Yi; Qi, Xiaoying; Yeung, Joanna; Xu, Wei.

In: British Journal of Haematology, Vol. 139, No. 1, 10.2007, p. 51-54.

Research output: Contribution to journalArticle

Chang, Hong ; Ning, Yi ; Qi, Xiaoying ; Yeung, Joanna ; Xu, Wei. / Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. In: British Journal of Haematology. 2007 ; Vol. 139, No. 1. pp. 51-54.
@article{572b3ce8e52a4ea2bcd4670f4c832fd0,
title = "Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma",
abstract = "The combination of fluorescence in situ hybridization with cytoplasmic light chain detection identified chromosome 1p21 deletion in 18 (20{\%}) of 87 patients with multiple myeloma. 1p21 deletion was associated with higher serum calcium level, 13q deletion, and t(4;14). Patients with 1p21 deletions had a significantly shorter progression-free survival (PFS) (median 10.5 vs. 22.3 months, P = 0.0002) and shorter overall survival (OS) (median 33.9 months vs. not reached, P = 0.002) than those without 1p21 deletions. On multivariate analysis, which included deletions of 13q, TP53, t(4;14) and CKS1B amplification, 1p21 deletion remained as an independent risk factor for PFS (P = 0.01) and OS (P = 0.04).",
keywords = "1p21, CDC14A, Fluorescence in situ hybridization, Multiple myeloma, Prognosis",
author = "Hong Chang and Yi Ning and Xiaoying Qi and Joanna Yeung and Wei Xu",
year = "2007",
month = "10",
doi = "10.1111/j.1365-2141.2007.06750.x",
language = "English (US)",
volume = "139",
pages = "51--54",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma

AU - Chang, Hong

AU - Ning, Yi

AU - Qi, Xiaoying

AU - Yeung, Joanna

AU - Xu, Wei

PY - 2007/10

Y1 - 2007/10

N2 - The combination of fluorescence in situ hybridization with cytoplasmic light chain detection identified chromosome 1p21 deletion in 18 (20%) of 87 patients with multiple myeloma. 1p21 deletion was associated with higher serum calcium level, 13q deletion, and t(4;14). Patients with 1p21 deletions had a significantly shorter progression-free survival (PFS) (median 10.5 vs. 22.3 months, P = 0.0002) and shorter overall survival (OS) (median 33.9 months vs. not reached, P = 0.002) than those without 1p21 deletions. On multivariate analysis, which included deletions of 13q, TP53, t(4;14) and CKS1B amplification, 1p21 deletion remained as an independent risk factor for PFS (P = 0.01) and OS (P = 0.04).

AB - The combination of fluorescence in situ hybridization with cytoplasmic light chain detection identified chromosome 1p21 deletion in 18 (20%) of 87 patients with multiple myeloma. 1p21 deletion was associated with higher serum calcium level, 13q deletion, and t(4;14). Patients with 1p21 deletions had a significantly shorter progression-free survival (PFS) (median 10.5 vs. 22.3 months, P = 0.0002) and shorter overall survival (OS) (median 33.9 months vs. not reached, P = 0.002) than those without 1p21 deletions. On multivariate analysis, which included deletions of 13q, TP53, t(4;14) and CKS1B amplification, 1p21 deletion remained as an independent risk factor for PFS (P = 0.01) and OS (P = 0.04).

KW - 1p21

KW - CDC14A

KW - Fluorescence in situ hybridization

KW - Multiple myeloma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=34548569309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548569309&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06750.x

DO - 10.1111/j.1365-2141.2007.06750.x

M3 - Article

C2 - 17854306

AN - SCOPUS:34548569309

VL - 139

SP - 51

EP - 54

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -